Effects of incretin-based therapies on neurocognitive function in humans: A systematic review of the literature

This publication has 11 references indexed in Scilit:

• Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: Findings from the South London Diabetes (SOUL-D) Study
  Primary Care Diabetes, 2016
• GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial
  Diabetologia, 2016
• Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System
  Diabetes, 2015
• Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
  Journal of Parkinson’s Disease, 2014
• Dipeptidyl Peptidase-4 Inhibitors Have Protective Effect on Cognitive Impairment in Aged Diabetic Patients With Mild Cognitive Impairment
  The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2014
• Cognitive and Functional Influences of Vildagliptin, a DPP-4 Inhibitor, Added to Ongoing Metformin Therapy in Elderly with Type 2 Diabetes
  Endocrine, Metabolic & Immune Disorders - Drug Targets, 2013
• Subcutaneous Administration of Liraglutide Ameliorates Alzheimer-Associated Tau Hyperphosphorylation in Rats with Type 2 Diabetes1
  Journal of Alzheimer’s Disease, 2013
• The global prevalence of dementia: A systematic review and metaanalysis
  Alzheimer's & Dementia, 2013
• Incretin-based therapies for type 2 diabetes mellitus
  Nature Reviews Endocrinology, 2009
• Treatment of Alzheimer's disease; current status and new perspectives
  The Lancet Neurology, 2003